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KidneyCurrent Management of Patients
With Acquired Solitary Kidney
Ekamol Tantisattamo1,2,3, Donald C. Dafoe4, Uttam G. Reddy1,2, Hirohito Ichii4,
Connie M. Rhee1,2, Elani Streja1,2, Jaime Landman5 and Kamyar Kalantar-Zadeh1,2,6
1Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology, Hypertension and Kidney
Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA;
2Nephrology Section, Department of Medicine, Veterans Affairs Long Beach Healthcare System, Long Beach, California, USA;
3Multi-Organ Transplant Center, Section of Nephrology, Department of Internal Medicine, William Beaumont Hospital, Oakland
University William Beaumont School of Medicine, Royal Oak, Michigan, USA; 4Division of Kidney and Pancreas Trans-
plantation, Department of Surgery, University of California Irvine School of Medicine, Orange, California, USA; 5Department of
Urology, University of California Irvine School of Medicine, Orange, California, USA; and 6Los Angeles Biomedical Research
Institute at Harbor-UCLA Medical Center, Torrance, California, USAPersons with acquired solitary kidney, including those who have had a unilateral nephrectomy for living
kidney donation, renal malignancies, or trauma, have decreased renal mass that leads to increased
intraglomerular pressure and glomerular hyperﬁltration. These physiologic adaptations of solitary kidney
may exacerbate other preexisting and genetic conditions that could create a predisposition to or worsen
glomerular pathologies, leading to unfavorable renal outcomes. Hence, these persons may beneﬁt from
special care and lifestyle modiﬁcations, including nutritional interventions. There is a lack of consensus
and evidence for proper surveillance and management after nephrectomy, and misconceptions in both
directions of having a “normal” versus “abnormal” kidney status may cause confusion among patients
and healthcare providers pertaining to long-term kidney health monitoring and management. We have
reviewed available data on the impact of lifestyle modiﬁcations, particularly nutritional measures, and
pharmacologic interventions, on short- and long-term outcomes after nephrectomy. We recommend
avoidance of excessively high dietary protein intake (>1 g/kg per day) and high dietary sodium intake (>4
grams/d), adequate dietary ﬁber intake from plant-based foods, a target body mass index of <30 kg/m2 (in
non-athletes and non-bodybuilders), and judicious management of risk factors of progressive chronic
kidney disease (CKD), and future studies should help to better determine optimal care practices for these
persons.
Kidney Int Rep (2019) 4, 1205–1218; https://doi.org/10.1016/j.ekir.2019.07.001
KEYWORDS: chronic kidney disease; dietary management; living donor renal transplantation; nephrectomy; protein-
uria; solitary kidney
ª 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C KD, which exists in over 10% of the adults with 2kidneys, can develop in persons with a solitary
kidney and may progress to end-stage renal disease
(ESRD) resulting in high physical and psychological
burdens in addition to extraordinary healthcare costs.
Whereas in the past, nephrectomy for living kidney
donation was considered to be safe without a higher
likelihood of CKD,1 more recent data suggest that there
is a 3–5 times higher relative risk of ESRD after a uni-
lateral nephrectomy, while the absolute risk remainsspondence: Kamyar Kalantar-Zadeh, Division of Nephrology,
tension and Kidney Transplantation, Department of Medi-
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International Reports (2019) 4, 1205–1218small.2–4 The pathogenesis of CKD and ESRD in kidney
donors with a solitary kidney may be different from
that in those CKD patients without nephrectomy.
Glomerulonephritis appears to be the most common
renal disease, leading to early ESRD in living kidney
donors, and underlying genetic predispositions may
contribute to faster progression of CKD to ESRD in
some groups of living kidney donors.5 Misconceptions
in both directions of having a “normal” versus
“abnormal” kidney status cause confusion among pa-
tients and healthcare providers pertaining to long-
term management.
According to the conventional deﬁnition and staging
of CKD, persons with only one kidney from congenital
or acquired causes, such as donor nephrectomy, are
classiﬁed as CKD patients. Physiological adaptation in
solitary kidney leads to higher glomerular ﬁltration
rates (GFRs) relative to units of nephron, which can1205
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ﬁltration, but in the long-term, it may lead to a gradual
decline in kidney function, and this trend can happen
even in living kidney donors. The progression to ESRD
may be related to unrevealed intrinsic risks of kidney
diseases such as genetic aberrations.6 The resultant
burden on kidney health, particularly if aggravated by
other causes of glomerular hyperﬁltration, such as high
dietary protein intake, may lead to de novo glomerular
diseases such as secondary focal segmental glomerulo-
sclerosis (FSGS), and may accelerate other preexisting
glomerular pathologies. Similar to most other causes of
CKD, clinical manifestation of solitary kidney is silent.
Therefore, initial screening for signs of worsening renal
function and accurately determining renal function are
warranted. In addition to usual approaches for CKD
management, lifestyle modiﬁcation including nutri-
tional and dietary interventions can be considered for
persons with a solitary kidney, and may be com-
plemented by certain pharmacologic interventions, as
reviewed in this article.
Epidemiology of Solitary Kidney
Congenital solidary kidney, also known as unilateral
renal agenesis, occurs in a ratio of about 1:1000, often
on the left, with a male-to-female ratio of 1.8:1.7
Acquired solitary kidney after a unilateral radical ne-
phrectomy in adults is mainly due to living kidney
donation, renal tumor, and trauma. Over the last 30 years,
rate of living kidney donation had gradually increased
from 1800 donations in 1998 to 6600 donations in 2004.
However, it has decreased since 2011 and has been stable
around 5650 kidney donations per year.8 The most com-
mon age range of living kidney donors is 35 to 49 years.9
The incidence of renal cell carcinoma is 63,990 cases
each year. The risk for developing renal cancer
signiﬁcantly increases in individuals aged >60 years,
and males are at an almost 2 times greater risk than
females.10 There were 10,123 and 4299 radical ne-
phrectomies performed during 1991–2002 and 1992–
2007, respectively, due to renal cell carcinoma.11
The incidence of renal trauma is varied. One study
reported 757 radical nephrectomies among 9002 renal
trauma patients from 2002–2007.12 Young adult males
are the most commonly affected population.
Pathophysiological Changes in Patients With a
Solitary Kidney
GFR is correlated with the number of nephrons, and it
may vary by age, gender, and body habitus. Loss of
nephrons is usually not a cause of decreased GFR, owing
to compensatory mechanisms, although these do not
provide full compensation and GFR increases to 65%–
70% of pre-donation GFR in healthy donors aged <601206years.13 Since the excretory function of kidney is needed
to maintain ﬂuid, electrolyte, and mineral balances,
physiological adaptation occurs immediately after ne-
phrectomy, with increases in effective renal plasma
ﬂow, glomerular ultraﬁltration coefﬁcient (Kf), and
transcapillary hydraulic pressure gradient (DP), leading
to increased single-nephron GFR, glomerular hyper-
ﬁltration, and overall increased GFR.14,15
In addition to renal hemodynamic change after ne-
phrectomy, structural nephron alteration in the form of
both hypertrophy and hyperplasia may occur.16 This
compensatory glomerular hypertrophy is involved in
several pathways including activation in mammalian
target of rapamycin complex (mTOR), interleukin 10,
and transforming growth factor-b.17 However, this
compensatory mechanism postnephrectomy in living
kidney donor differs from patients after nephrectomy
from other reasons.18
The compensatory glomerular hyperﬁltration can
cause damage to the solitary kidney in the long term,
especially if there are other factors that would aggravate
glomerular hyperﬁltration, such as high dietary protein
intake resulting in afferent arteriole dilation and leading
to intraglomerular hypertension, or high dietary sodium
intake resulting in increases in systemic hypertension
and volume retention.19,20 Intraglomerular hypertension
causes podocyte injury and loss of perm-selectivity of
the ﬁltrating function of the slit diaphragm between foot
processes, causing proteinuria. In addition, endothelial-
mesangial hyperplasia and glomerulomegaly mediated
by increased transforming growth factor-b1 and angio-
tensin II cause podocyte detachment from glomerular
basement membrane and subsequently glomerulo-
sclerosis.21 These ultimately lead to pathological changes
similar to those seen in FSGS and albuminuria, a decline
in GFR, and CKD progression (Figure 1).
Consequence of Acquired Solitary Kidney After
Radical Nephrectomy
As discussed above, native nephrectomy causes
glomerular hypertension and hypertrophy and patho-
logical changewith FSGS, which are associatedwith poor
renal outcomes. Similar to common glomerular diseases
in patients with both kidneys such as minimal change
disease (MCD), FSGS, and diabetic nephropathy, glo-
merulomegaly and enlarged kidney size are associated
with progression of CKD.22 In addition, glomerular hy-
pertrophy secondary to nephronopenic change in long-
surviving transplant renal allograft is associated with
FSGS.23 In acquired solitary kidney patients, histologic
changes also lead to poorer renal and patient outcomes.
The severity of progressive renal dysfunction and
long-term renal outcomes are determined by the
remaining nephron masses immediately afterKidney International Reports (2019) 4, 1205–1218
Acquired unilateral native nephrectomy
Renal hemodynamic change Glomerular structural change
• ×ERPF
• ×Kf
• ×∆P
×SNGFR
Glomerular hyperfiltration Glomerular hypertrophy×Intraglomerular pressure
Podocyte injury
ProteinuriaGlomerulosclerosis
Pathways of cell 
regulation, e.g.,
• mTOR
• IL-10
• TGF-β 
Secondary FSGS
Figure 1. Pathophysiological changes after unilateral native nephrectomy. ERPF, effective renal plasma ﬂow; FSGS, focal segmental glomer-
ulosclerosis; GFR, glomerular ﬁltration rate; IL-10, interleukin-10; Kf; glomerular ultraﬁltration coefﬁcient; mTOR, mammalian target of rapamycin;
SNGFR, single-nephron glomerular ﬁltration rate; TGF-b, transforming growth factor-beta; DP; transcapillary hydraulic pressure gradient.
E Tantisattamo et al.: Postnephrectomy Management REVIEWnephrectomy, the duration of having a solitary kidney,
concomitant comorbidities, and lifestyle, including
dietary habits (Figure 2). Pediatric patients with
congenital solitary kidney, even with subclinical de-
fects, carry a greater risk for developing ESRD
compared with those who have unilateral or bilateral
renal hypodysplasia, or multicystic or horseshoe kid-
ney.24 Unilateral nephrectomy due to renal trauma and
from living kidney donation is common in young and
middle-aged persons, respectively, whereas kidney
malignancies are more common in older age groups,Congenital solitary kidney
Pediatric 
patients
- Secondary 
FSGS from low 
birth weight, 
premature birth
- Associated 
renal anomalies 
from the 
contralateral 
remaining 
kidney
Renal trauma
Young adults
- Concomitant 
AKI
- Multi-organ 
failure
Livin
Adul
Chronic kidney
Figure 2. Etiologies of solitary kidney across age groups and factors deter
onset of having a solitary kidney and concomitant underlying renal anoma
on age at the onset of solitary kidney, also leads to possible cumulative li
AKI, acute kidney injury; FSGS, focal segmental glomerulosclerosis.
Kidney International Reports (2019) 4, 1205–1218who are more likely to have underlying comorbidities,
which increases the risk of CKD. In this review, we
discuss the outcomes of acquired solitary kidney.
Living Kidney Donation
One cohort showed no increased risk of developing
ESRD or mortality among donors.1 However, more
recent studies have consistently demonstrated
increased long-term risk of ESRD2–4 and higher mor-
talities.2 Table 11–4 shows long-term outcomes in living
kidney donors from 4 recent clinical studies. However,g kidney donation
ts Renal tumor
Elderly
- Underlying 
medical 
comorbidities 
and CKD
 disease
mining long-term renal function, including nephron mass at the initial
lies or comorbidities. Duration of having a solitary kidney, depending
fetime risk for developing progressive chronic kidney disease (CKD).
1207
Table 1. Summary of long-term outcomes in living kidney donors from 4 recent clinical studies
Reference Study design Study population Duration of follow-up
Results
ESRD Mortality Proteinuria Hypertension Additional outcomes
Ibrahim et al.
20091
Single center; living
kidney donation
1963 through 2007;
study period 2003–
2007
3698 living kidney donors
vs. matched (1:1)
controls based on age,
sex, and race or ethnic
group
Mean (SD) of 12.2
 9.2 yr after
donation
Development of ESRD in 11 living
kidney donors (180 cases/million
persons per year) vs. 268 cases/
million per year in general population;
GFR of $60 ml/min per 1.73 m2
of BSA in 85.5% of donor subgroupa
Death in 268 donors;
donor survival
appeared to be
similar to that of
controls in general
population
Albuminuria 12.7%
of donor subgroupa; a
longer time since
donation was
associated with
albuminuria
Hypertension in
32.1% of donor
subgroupa
Older age and higher BMI
were associated with a GFR
of <60 ml/min per 1.73 m2
and hypertension
Mjoen et al.
20142
Single center; living
kidney donation
1963 through 2007
1901 living kidney donors
vs. 32,621
controls who would have
been eligible for donation
A median follow-up of
15.1 yr (living kidney
donors) and 24.9 yr
(control group)
Development of ESRD in 9 living kidney
donors (302 cases/million) vs. 22
controls;
HR for ESRD 11.38 (95% CI,
4.37–29.6)
HR for all-cause
mortality 1.30 (95%
CI, 1.11–1.52) and
for cardiovascular
death 1.40 (95% CI,
1.03–1.91), for
donors compared
with controls
NA NA NA
Muzaale et al.
20143
Population-based
study
96,217 living kidney
donors in the US, per
OPTN between April 1994
and November 2011 vs.
20,024 matched healthy
participants of the
NHANES III between 1988
and 1994
Maximum follow-up
of 15.0 yr; median
follow-up of 7.6 yr
(IQR: 3.9–11.5 yr)
for kidney donors vs.
15.0 yr (IQR 13.7–
15.0 yr) for matched
healthy nondonors
Development of ESRD in 99 donors in a
mean (SD) of 8.6 (3.6) yr after
donation vs. 36 matched healthy
nondonors in 10.7 (3.2) yr;
estimated risk of ESRD at 15 yr after
donation was 30.8 per 10,000 (95%
CI, 24.3–38.5) in kidney donors and
3.9 per 10,000 (95% CI, 0.8–8.9) in
their matched healthy nondonors (P <
.001); estimated lifetime risk of ESRD
was 90 per 10,000 donors vs. 326 per
10,000 unscreened nondonors
(general population) vs. 14 per
10,000 healthy nondonors
An estimated risk of ESRD
was highest in black donors
and lowest in white
nondonors
Grams et al.
20164
A meta-analysis of 7
general-population
cohorts, calibrated to
the population-level
incidence of ESRD
and mortality in
the US
52,998 living kidney
donors in the US vs.
4,933,314 nondonors
from 7 cohorts
Median of 4 to 16 yr Projected 15-yr observed risk of ESRD
3.5 to 5.3 times greater in living kidney
donors compared to age-matched
nondonors
Projected 15-yr risk of ESRD
in nondonors depending on
race and sex; (highest in
black men and lowest in
white women)
BMI, body mass index; BSA, body surface area; CI, conﬁdence interval; ESRD, end-stage renal disease; HR, hazard ratio; IQR, interquartile range; NA, not available; NHANES III, Third National Health and Nutrition Examination Survey; OPTN, Organ
Procurement and Transplantation Network.
aGlomerular filtration rate (GFR) and urinary albumin excretion and were measured in a total of 255 donors from 2003 through 2007, and the prevalence of hypertension was examined.
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E Tantisattamo et al.: Postnephrectomy Management REVIEWthese epidemiologic studies followed living kidney
donors for up to only 2 decades. Recent clinical in-
vestigations to understand the long-term pathophysi-
ologic change of the remaining kidney in living
kidney donors with a median follow-up of 6.3 years
demonstrated that adaptive glomerular hyperﬁltration
and hypertrophy, but not glomerular hypertension,
persists after donor nephrectomy, due to increased
renal plasma ﬂow and heightened Kf.25 This glomer-
ular hyperﬁltration in living kidney donors is
different from the glomerular hyperﬁltration in dia-
betic kidney disease that results from increased
glomerular hydraulic pressure (PGC).
26 In addition, a
recent retrospective study with long-term follow-up of
living kidney donors showed that postdonation GFR
steadily increased for several years until donors
reached 70 years of age.6 Indirect evidence of early
signs of CKD was a higher level of serum intact
ﬁbroblast growth factor 23, and renal tubular frac-
tional excretion of inorganic phosphorus, as well as
lower serum phosphorus and calcitriol levels in living
kidney donors compared with nondonor controls.27
Kasiske et al.28 reported laboratory changes in living
donors that were consistent with the ﬁndings in pa-
tients with mild CKD, including higher levels of serum
parathyroid hormone, uric acid, homocysteine, and
potassium, but a lower level of hemoglobin compared
with a control group.28 Hence, there is consistent ev-
idence to suggest that unilateral radical nephrectomy
for living kidney donation may increase the overall
risk of progressive CKD, even though the absolute risk
is likely small.
Common causes of advanced CKD and ESRD in living
kidney donors include diabetes mellitus, hypertension,
and glomerulonephritis and are similar to those in the
non-nephrectomized population; however, the time of
ESRD onset may be different. A study of 125,427 living
kidney donors with a median follow-up of 11 years
showed that glomerulonephritis was the most common
cause of ESRD during the ﬁrst 10 years after kidney
donation, whereas diabetes and hypertension were
more common thereafter.5 The pathogenesis of ESRD in
living kidney donors involves not only glomerular
hyperﬁltration but also intrinsic factors, which may
explain an earlier onset of ESRDs such as genetic kid-
ney diseases including apolipoprotein L1–related dis-
ease; the 2017 Kidney Disease Improving Global
Outcomes guidelines have suggested that apolipopro-
tein L1 genotyping be offered in potential living kid-
ney donors with sub-Saharan African ancestors.29
Although the most recent large retrospective cohort
studies demonstrated an 8–11 times greater risk for
ESRD in living donors, absolute risk was very low.
Residual confounders were non-perfectly matchedKidney International Reports (2019) 4, 1205–1218controls for donors in both studies.2,3 Two small
studies utilized siblings of the donors to achieve better-
matched controls and showed no increased risk for
ESRD in living donors.30,31 From the aforementioned
study, the second “hit” to living donors from immu-
nologic- or environmental-related renal diseases, not
CKD progression or FSGS due to hyperﬁltration, is
likely the major reason of ESRD.1,2,5
The baseline functioning nephrons that everyone
has at birth, also known as “nephron endowment,”
may determine the risk for CKD and may need to be
taken into consideration during living-donor
evaluation.32
Several studies have demonstrated a positive corre-
lation between the number of nephrons and birth
weight. Infants with low birth weight, either preterm
infants with appropriate weight for gestational age, or
term infants with small for gestational age, have a
decreased number of nephrons and an increased risk of
hypertension, cardiovascular diseases (CVDs), and
progressive CKD leading to ESRD. In adults, several
studies revealed an association between low birth
weight and higher blood pressure (BP), as well as be-
tween low birth weight and microalbuminuria and
proteinuria. A meta-analysis showed that low birth
weight is associated with a 70% increased risk of CKD
deﬁned as albuminuria, low estimated GFR (eGFR; <60
ml/min per 1.73 m2 or <10th percentile for age/sex), or
ESRD.32 Hence, it is biologically plausible that solitary
kidney, by virtue of having 50% lower nephron
endowment, results in a higher risk of progressive
CKD. However, there is a U-shape relationship between
birthweight and CKD in men, and high birth weight
($4500 mg) was found to be associated with CKD,
possibly from maternal and future insulin resistance in
men.33
A higher ratio of donor kidney weight to recipient
body weight is associated with lower levels of pro-
teinuria in deceased donor recipients and better 3-year
outcomes in living donor recipients.34 Kidney trans-
plant recipients with higher transplant kidney cross-
sectional area divided by recipient body weight had
higher 5-year renal allograft function.35 Given that
history of low birth weight, age, and gender are asso-
ciated with nephron number, information on these
factors may be useful when evaluating potential living
kidney donors, informing renal prognosis after living
kidney donation, and appropriately selecting potential
living kidney donors to match recipient demand.
Based on the original CKD deﬁnition, a person with
structural damage to a kidney, including partial or
radical nephrectomy, has CKD, even if GFR is normal
without albuminuria (<30 mg/g of creatinine). How-
ever, the justiﬁability of labeling a living kidney donor1209
REVIEW E Tantisattamo et al.: Postnephrectomy Managementor even cancer nephrectomized patient as having CKD
remains debatable given that such a “diagnosis” may
have a wide range of psychosocial implications and
may affect employment and health insurable eligibility.
Nevertheless, we believe that periodic assessment of
“kidney function of donor” is a critical responsibility
of healthcare providers, given the higher than normal
risk of developing ESRD in living kidney donors, and
notwithstanding the fact that the absolute risk remains
small.
Unilateral Native Nephrectomy for Renal Cancer
Patients with kidney cancer who undergo unilateral
nephrectomy are likely to encounter a long-term higher
risk for CKD and subsequently higher mortality,
compared with the general population. However, a
signiﬁcant proportion of these patients may have pre-
existing CKD. A retrospective cohort of 4633 patients
diagnosed with renal cell carcinoma showed that 11%
of patients undergoing partial nephrectomy developed
CKD; up to 20% of patients with radical nephrectomy
had CKD; and the incidence of ESRD was 2% and 4%
after partial and radical nephrectomy, respectively.36
In another study of 7073 US veterans who had a par-
tial or radical nephrectomy between 2004 and 2013,
mostly for kidney cancer, worse postnephrectomy
kidney function and higher mortality were observed
with radical nephrectomy, and a low presurgical eGFR
and a greater decrease in eGFR postsurgery were
associated with higher mortality, irrespective of the
type of nephrectomy.37
Unilateral Native Nephrectomy After Renal Trauma
Renal trauma patients requiring unilateral nephrec-
tomy is another group with a solitary kidney whose
contralateral renal function determines a long-term
renal outcome. The incidence of acute renal failure af-
ter nephrectomy for renal trauma is 5%–10%.38
Several factors increase the risk of renal failure,
including the patient’s age, other organ injury, and
multi-organ failure. The prevalence of CKD or CKD
progression in renal trauma patients with unilateral
nephrectomy is unclear, but subgroups of these pa-
tients who are at higher risk for developing CKD are
likely to be those who had acute kidney injury or
worsening underlying CKD from trauma or after
nephrectomy.
Cardiovascular Risk in Solitary Kidney
As with the general population, CVD is an important
cause of morbidity in living kidney donors. Even in
relatively older living kidney donors ($55 years old),
their combined mortality and CVD did not differ from
matched healthy older individuals.39 However, a
decreased GFR in living kidney donors may lead to1210higher cardiovascular risk. Moody et al.40 demon-
strated that living kidney donors had signiﬁcant in-
creases in left ventricular mass-to-volume ratio but
decreases in aortic distensibility and global circumfer-
ential strain compared with healthy controls at 12-
months postdonation. In that study, mean changes in
GFR during a 12-month follow-up were –28  11 and 3
 11 ml/min per 1.73 m2 in donor and control groups,
respectively.
Care for Persons with a Solitary Kidney
To prevent CKD or slow progression of a pre-existing
CKD in a person with a solitary kidney, non-
pharmacologic interventions should be utilized,
although concurrent pharmacologic interventions may
be used in selected patients.
Nonpharmacologic Interventions
Low-Protein Diet. Evidence suggests that high di-
etary protein intake is associated with higher risk for
CKD or faster CKD progression, because it leads to
afferent arteriolar vasodilatation which in turn in-
creases intraglomerular pressure.20 Whereas a high-
protein diet leads to an initial increase in GFR, in
the long-term, increased intraglomerular pressure
can lead to glomerular hyperﬁltration and loss of
kidney function (Figure 3).19 A population-based
study involving 1522 middle-age persons with a
mean eGFR of 84.0  11.4 ml/min per 1.73 m2 showed
a positive cross-sectional correlation between protein
intake and GFR, but after a mean follow-up of 12
years, every 1 g/d increase in protein intake was
associated with a 4.1 ml/min per 1.73 m2 decline in
eGFR (95% conﬁdence interval 5.1, 3.1) and a
78% higher risk for incidence of CKD deﬁned as
eGFR <60 ml/min per 1.73 m2 (95% conﬁdence in-
terval 1.15, 2.78).41
Several experimental studies and clinical trials
demonstrated a beneﬁcial effect of low dietary pro-
tein intake on slowing CKD progression, whereas a
high protein intake increases risk of renal failure. A
cross-sectional study in more than 4000 persons
showed an association between a high-protein diet
and increased GFR, with a sigmoid relationship be-
tween GFR and overnight urinary urea nitrogen,
with the threshold around the recommended daily
allowance for protein intake of 0.8 g/kg per day.42
Moreover, there is evidence of a linear relationship
between the amount of protein intake and a decrease
in eGFR.19
The quality of the protein may also play a role.
Several epidemiologic studies reveal the beneﬁt of
plant-based proteins over an animal-based diet.43 Data
from an 11-year follow-up among female participantsKidney International Reports (2019) 4, 1205–1218
High-protein diet
Change in renal 
hemodynamic
“Glomerular hyperfiltration”
• ×Renal blood flow
• ×Intraglomerular 
pressure
Sulfar-containing 
amino acid
High salt intake
Glomerulotubular damage
• Podocytopathy
• Tubular cell injury
Proteinuria
Direct vascular injury
Reactive oxygen 
species
• ×Nitric oxide
• ×TGF-β1
Oxidative stress
Shear stress 
Vascular injury
Hemodynamic effect ×Vasopressin
×GFR
Dehydration
CKD progression
Metabolic 
acidosis
Solitary functioning kidney after acquired unilateral native nephrectomy
Figure 3. Mechanism of renal injury from high-protein diet, high salt intake, and dehydration. CKD, chronic kidney disease; GFR, glomerular
ﬁltration rate; TGF-b1, transforming growth factor-beta 1.
E Tantisattamo et al.: Postnephrectomy Management REVIEWwith an eGFR >55 to <80 ml/min per 1.73 m2 showed a
signiﬁcant decline in eGFR of 1.21 ml/min per 1.73 m2
per 10-g increase in nondairy animal protein intake.44
Another prospective cohort study of 11,952 patients
with an eGFR >60 ml/min per 1.73 m2 showed an as-
sociation between an increased risk of CKD and red and
processed meat intake, but a decreased risk of CKD is
associated with a diet with nuts, low-fat dairy prod-
ucts, and legumes.45
The diet should include adequate ﬁber from plant-
based sources, as does the Dietary Approaches to
Stop Hypertension (DASH) diet and other diets listed
in Table 2, and the amount of daily protein should be
adjusted by level of renal function and proteinuria.19
It is often recommended that patients with hyper-
tension follow an energy-controlled DASH diet,
which is high in complex carbohydrates including
fruits, vegetables, and whole grains, as well asTable 2. The contemporary “healthy” diets in Western societies and sug
Diet type Features
DASH diet (Dietary Approaches
to Stop Hypertension)
Mix of fruits, vegetables, whole grains, lean protein, and l
Mediterranean diet High in fruits and vegetables, as well as healthy fatty foo
nuts, and olive oil
MIND diet A mix of DASH and the Mediterranean diet
Flexitarian diet A blend of the words ﬂexible and vegetarian; eat vegetarian
time for better health
Weight Watchers The PointsPlus system encourages consumption of fruit,
and ﬁber-rich foods, and discourages consumption of hi
energy-dense foods
TLC diet (Therapeutic
Lifestyle Changes)
To lower high cholesterol
Volumetrics To pay attention to the energy density in foods
aNote that in addition to the listed diet, vegetarian or vegan diet can also be recommended.
Kidney International Reports (2019) 4, 1205–1218legumes, and low in animal-based protein such as
meat, saturated fat, reﬁned grains, sweets, and pro-
cessed food. These dietary strategies may help with
weight maintenance or reduction in weight gain in
obesity.
No human study shows the beneﬁts of a low-
protein diet in protecting renal outcomes after ne-
phrectomy, and a typically low dietary protein
intake, such as 0.6–0.8 g/kg per day, which is rec-
ommended to patients with an eGFR <45 ml/min per
1.73 m2 or proteinuria >0.3 g/d, may not be needed
for healthy kidney donors.19 However, we believe
that it is wise to avoid a high protein intake of greater
than 1 g/kg per day, except in the case of profes-
sional athletes or bodybuilders with well thought-
out calculations on the needed protein amounts for
anabolic goals. Currently, there are no data to
corroborate these suggestions.gestions for persons with a solitary kidneya
Relevance to solitary kidney care
ow-fat dairy A preferred diet for persons with solitary kidney
ds like ﬁsh, Mediterranean diet is favorable as long as excessive protein intake of
>1 g/kg per day and high sodium intake of >4 g/d are avoided
Acceptable diet regimen
most of the Acceptable diet for persons with solitary kidney as long as high salt
intake of >4 g/d is avoided
vegetables,
gh-fat and
Excessive protein intake of >1 g/kg per day to be avoided
Excessive protein intake of >1 g/kg per day and high sodium intake
of >4 g/d to be avoided
Excessive protein intake of >1 g/kg per day and high sodium intake
of >4 g/d to be avoided
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cause direct vascular injury even without hypertension
and indirect renal damage from hemodynamic mecha-
nisms mediated by elevated BP and proteinuria. Similar
to a high-protein diet, a high-sodium diet leads to
increased intraglomerular pressure, causing glomerular
hyperﬁltration and subsequently renal injury
(Figure 3).19 A recent meta-analysis demonstrated no
preventive beneﬁt for CKD progression from reducing
sodium intake in the long term,46 and one longitudinal
study using serial 24-hour urine collections in 3939 CKD
patients suggested that the highest versus lowest quartile
of urinary sodium excretion ($4.5 vs. <2.7 g/d) was
associated with 45% higher mortality and 54% greater
risk of disease progression.47 Incrementally worse car-
diovascular outcomes were observed when dietary so-
dium intake exceeded 4 g/day.48 However, recent
observations in the general population suggest that there
is a J-shaped association in which both higher and lower
dietary sodium intake (>5 and <3 g/d) were associated
with higher risk of CVD and death.49 A prospective
study in 95,676 participants without CVD demonstrated
that a mean sodium intake of >5 g/d was associated with
stroke but not cardiovascular events.50
In a recent prospective cohort study of 3106 hyper-
tensive and 4871 nonhypertensive persons, in whom
28% of hypertensive and 17% of nonhypertensive pa-
tients developed CKD (eGFR <60 ml/min per 1.73 m2)
over a 10- to 11-year follow-up, respectively, hyperten-
sive patients with sodium intake of<2.1 and>4 g/d had
a signiﬁcantly higher incidence of CKD than those with
sodium intake between 2.9 and 4 g/d.51 We recommend
avoiding a diet with >4 g/d of sodium in individuals at
higher risk of developing future CKD, including those
with a solitary kidney.19 Studies are needed to further
delineate this area in persons with a solitary kidney.
Weight Control. Even in living kidney donors who are
determined to be healthy individuals, obese donors had
a 1.86 times higher risk of ESRD over 20 years
following nephrectomy compared to nonobese donors,
and overweight donors exhibited incrementally a 7%
higher risk of ESRD52 for every 1 kg/m2 higher body
mass index above 27 kg/m2. Nevertheless, in persons
with more advanced CKD, including dialysis patients, a
paradoxically greater longevity has been reported with
larger body size, known as the obesity paradox or
reverse epidemiology, possibly reﬂecting a more resil-
ient nutritional proﬁle and muscle mass.53 Hence, any
unintentional edema-free weight loss warrants timely
work-up, and dietary interventions may be considered
in those with more advanced CKD. We recommend a
target body mass index of <30 kg/m2 in non-athletes
and non–bodybuilders with a solitary kidney.1212Adequate Hydration. Both animal and human studies
demonstrate the inverse relationship between ﬂuid
intake and the long-term trajectory of GFR and risk of
proteinuria. The mechanism of an increased GFR with
low ﬂuid intake may be related to increased secretion of
vasopressin.54 Higher vasopressin also leads to
increased urinary albumin excretion,55 and dietary
protein also increases vasopressin secretion in humans
(Figure 3).56 One study demonstrated a beneﬁcial effect
of increased ﬂuid intake in preventing CKD or its
progression at earlier stages.57 However, few studies
suggested the opposite results.58 We suggest adequate
to generous ﬂuid intake (>2.5 L/day) in persons with a
solitary kidney and eGFR >60 ml/min per 1.73 m2, as
long as there is no material risk of hyponatremia.
Smoking Cessation. Smoking is a known risk for
many pathologies including CKD, based on some but
not all studies, and may worsen CKD progression.59
Smokers have 76% higher 15-year projections of
ESRD risk in the absence of kidney donation compared
with nonsmokers. The risk is attenuated but still as
high as 45% in former smokers.4 Living kidney donors
who smoked do not appear to have increased surgical
mortality risk compared with nonsmokers; however,
they had 5.3 times greater adjusted mortality risk over
4 years.60 Smoking cessation may slow the rate of renal
function deterioration in CKD patients.61 Persons with
solitary kidney should be advised routinely to avoid
smoking.
Physical Activity After Nephrectomy. After nephrec-
tomy, physical and functional, as well as mental, changes
from postoperative recovery, including pain, are associ-
ated with outcomes. Evidence showed that exercise im-
proves some side effects for cancer, quality of life, and
survival, via alteration in neuro-hormones, cell growth
regulatory pathway, gene expression, and tumor im-
munity.62 Trinh et al.63 reported an association between
physical activity and quality of life in kidney cancer
survivors; however, 56% of those in the study popula-
tion were completely sedentary.63 Therefore, medical
providers for cancer patients still face this challenge but
have the opportunity to improve their patient’s out-
comes. For living kidney donors, physical activity im-
proves not only their health and weight control, but also
their mental health. Longer time to return to daily ac-
tivities after donor nephrectomy is associated with lower
satisfaction with life (SWL) as assessed by the SWL
scale.64Pharmacologic Interventions
Blood Pressure Control. An increased night-to-day
systolic BP ratio, and a decreased dipper pattern inKidney International Reports (2019) 4, 1205–1218
E Tantisattamo et al.: Postnephrectomy Management REVIEWCKD patients before, compared with after, a unilateral
nephrectomy have been reported in patients with
renal and/or ureteral cancer.65 However, the level of
BP by 24-hour BP monitoring, and the circulating
renin–angiotensin system, including plasma renin
activity and angiotensin II levels, are not altered. In
living kidney donors, BP does not appear to be
elevated in the short term,66 and similar data are re-
ported in long-term follow-up studies (up to 5 years)
and even in donors with pre-donation
hypertension.66
Landmark studies comparing BP targets for dia-
betes67,68 and nondiabetes,69 as well as the recent
guidelines70–72 for target BP are shown in Table 3.
According to the 2017 American College of Cardiology/
American Heart Association guidelines, a target BP
of <130/80 mm Hg, and a BP threshold to initiate
antihypertensive therapy of $140/90 mm Hg, are rec-
ommended for patients with no clinical CVD and a 10-
year atherosclerotic cardiovascular disease risk
of <10%; for patients with the latter risk of $10%,
antihypertensive medications should be initiated when
BP $ 130/80 mm Hg.72 There is no evidence for rec-
ommending any speciﬁc BP target in living kidney
donors. However, since most living kidney donors are
healthy and have no signiﬁcant comorbidity, a target
BP of <130/80 mm Hg may be appropriate. Until there
is strong evidence demonstrating that outcomes of
living kidney donors are related to BP, individualized
BP control appears to be appropriate.
Proteinuria Management in Solitary Kidney. Angio-
tensin pathway modulators including angiotensin
converting–enzyme inhibitors and angiotensin recep-
tor blockers are often used to improve proteinuria andTable 3. BP control and renal outcomes in major clinical trials and guide
BP Studies Population
Clinical trials for BP UKPDS67 Type 2 DM Inten
ACCORD68 Type 2 DM Inten
SPRINT69 Non-DM Inten
stand
Target BP
Guidelines for BP
targets
2017 ADA70 <140/90 mm Hg <13
JNC 871 <140/90 mm Hg
2017 ACC/AHA72 <130/80 (10-yr ASCVD
< or $10%)
$14
$13
ACC/AHA, American College of Cardiology/American Heart Association; ACCORD, Action to C
atherosclerotic cardiovascular disease; BP, blood pressure; DM, diabetes mellitus; GFR, glomer
Systolic Blood Pressure Intervention Trial; UKPDS, United Kingdom Prospective Diabetes Stud
Kidney International Reports (2019) 4, 1205–1218slow progression of renal disease. Renin–angiotensin
system blockade provides renoprotective and anti-
proteinuric effects in animals with nephrectomy,
including solitary kidney;73 however, there is limited
evidence of these effects of renin–angiotensin system
blockade in humans with a solitary kidney. Angio-
tensin converting–enzyme inhibitors and angiotensin
receptor blockers lower intraglomerular pressure by
dilating efferent arterioles more than afferent arterioles,
especially in patients with glomerular diseases, because
there is afferent arteriolar dilatation at baseline to
maintain GFR. As with a low-protein and low-sodium
diet, decreased intraglomerular pressure will mitigate
glomerular hyperﬁltration and may slow progression of
renal function decline.
Antiplatelet Agents. Evidence suggests that aspirin
lowers cardiovascular events in CKD and it may also
delay CKD progression.74 An epidemiologic study
showed that compared with nonregular aspirin users,
CKD patients using aspirin regularly had an 0.80 ml/
min per 1.73 m2/yr (95% conﬁdence interval 0.1, 1.5)
slower decline in GFR.75 However, a case–control study
showed paradoxically a 2.5-times greater risk of CKD in
patients regularly using low-dose aspirin ($ twice a
week for 2 months) compared with the nonaspirin
users.76 We currently have no recommendation for or
against intake of aspirin or other antiplatelet agents in
persons with an acquired solitary kidney.
Evaluation and Follow-up for Renal Function in
Solitary Kidney
After unilateral nephrectomy, patients often have
concerns pertaining to the risk of permanent loss of
renal function and the likelihood of development oflines for target BP that may be relevant to solitary kidney conditions
Compared groups Main results
sive vs. standard BP control No signiﬁcant difference in proteinuria, change in
serum creatinine, new-onset microalbuminuria,
except lower macroalbuminuria level in tight
BP compared with standard BP control
(6.6% vs. 87%; P <0.000 in ACCORD trial)
sive vs. standard BP control
sive (SBP <120 mm Hg) vs.
ard (SBP <140 mm Hg) BP
control
A signiﬁcant decrease in all cardiovascular
outcomes and all-cause mortality in intensive
group; a composite of renal outcomes
including the ﬁrst occurrence of a reduction in the
estimated GFR of $50%, long-term dialysis, or
kidney transplantation of 1% with no difference
between 2 groups
Threshold BP
0/80 mm Hg (patients with no
undue treatment burden)
0/90 (10-yr ASCVD <10%)
0/80 (10-yr ASCVD $10%)
ontrol Cardiovascular Risk in Diabetes; ADA, American Diabetes Association; ASCVD,
ular ﬁltration rate; JNC, Joint National Committee; SBP, systolic blood pressure; SPRINT,
y.
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Table 4. Characteristics of estimated and measured GFR in persons with a solitary kidney
GFR Clinical use Limitations
Clinical utilities for patients with a
solitary kidney
Estimated
Cockcroft-Gault equation When serum creatinine is stable; drug dosinga Determined by muscle mass in steady state
- Age
- Gender
- Race
10%–40% overestimate creatinine clearance
Estimate creatinine clearance, not GFR
Imprecise in CKD
Follow-up for stable renal function
MDRD Study equation Accurately estimate77 eGFR <60 ml/min per
1.73 m2; accurate in nonhospitalized CKD
Not precise77 when eGFR >60 ml/min
per 1.73 m2
Leading to overestimate CKD prevalence
Require steady state or stable renal function
Follow-up for stable renal function
CKD-EPI equation Can be used77 to estimate eGFRs >60 ml/min
per 1.73 m2
Compared to MDRD equation, CKD-EPI is better
for higher levels of GFR, diabetes, transplant
status, elderly, and at higher body mass index
Precision remains depending on creatinine
measurement
Renal cell carcinoma with
comorbidity, e.g., elderly, diabetes,
obesity
Living kidney donor whose renal
functions are generally normal
Cystatin C–based GFR Less affected by race and muscle wasting
Conditions causing variation of serum creatinine
Diabetes with high GFR
High-protein diet
Asian
Pregnant
Unusual muscle mass, body habitus, weight
(e.g., morbid obesity, amputees)
May lower precision compared with creatinine-
based GFR
Conﬁrm the result from creatinine-
based GFR
Consider in solitary kidney patients
who have hyperﬁltration
Creatinine-cystatin C–based
GFR
More precision and accuracy than creatinine-
based or cystatin-based equations
Not widely available Conﬁrm the result from creatinine-
based GFR
KeGFR Can be used during acute change of renal
function
Need subsequent serum creatinine measurement
to follow up the trend eGFR
Monitor renal function during early
postnephrectomy
Measured
Creatinine clearance Commonly used in clinical practice Affected by creatinine secretion, production,
measurement
Conﬁrm eGFR
Iothalamate clearance Radioactive of nonradioactive labels78 Iodine allergy
Tubular secretion causes bias in measuring GFR
(compared to urinary inulin clearance)79
Conﬁrm eGFR
Consider using in living kidney donors
Iohexol clearance Nonradioactive radiographic contrast agent78 Tubular reabsorption underestimates GFR from
iohexol plasma clearance compared to urinary
inulin clearance78
Iodine allergy
Conﬁrm eGFR
51Cr-EDTA Underestimates inulin clearance by 5% to 15% Conﬁrm eGFR
DTPA Short half-life (6 h) that minimizes radiation
exposure, high counting efﬁciency of 99mTc
GFR underestimation from dissociation of 99mTc
from DTPA and plasma protein binding78
Conﬁrm eGFR
Gadolinium-DTPA or
gadolinium-DOTA
A highly sensitive, immunoassay technique Rare complication of systemic nephrogenic
ﬁbrosis
CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology collaboration; 51Cr-EDTA, chromium-51 labeled ethylenediamine tetraacetic acid; DTPA, diethylenetriamine
pentaacetic acid; eGFR, estimated glomerular filtration rate; gadolinium-DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; gadolinium-DTPA, gadolinium-diethylenetri-
amine pentaacetic acid; KeGFR, kinetic eGFR; MDRD, Modification of Diet in Renal Disease; mGFR, measured glomerular filtration rate
aThe most accurate method for drug dosing, e.g., MDRD, CKD-EPI equations.
REVIEW E Tantisattamo et al.: Postnephrectomy ManagementESRD. Therefore, accurate estimated renal function is
critical to determine and monitor in these patients.
GFR Estimation and Monitoring
Several equations have been developed to estimate GFR
(Table 4).77–79 Endogenous and exogenous de-
terminants may cause deviations in variables in the
equations; therefore, an “estimated” GFR (eGFR), be it
based on serum creatinine or cystatin C, is not an ac-
curate method for assessing true GFR and may lead to
inaccuracies.77,78 The Kidney Disease Improving Global
Outcomes 2012 Clinical Practice Guideline for the
Evaluation and Management of CKD,80 and the 2017
Kidney Disease Improving Global Outcomes Clinical1214Practice Guideline on the Evaluation and Care of Living
Kidney Donors29 recommend that an initial assessment
for kidney function be conducted using serum creati-
nine and the eGFR equation, and that additional tests,
e.g., serum cystatin C or a clearance measurement, be
used as conﬁrmatory tests when eGFR based on serum
creatinine is less accurate. A major limitation of the
creatinine-based GFR equations is related to creatinine
production, renal creatinine secretion, extrarenal
creatinine excretion, and technical issues pertaining to
creatinine measurement. Several studies have demon-
strated that creatinine-based eGFR inaccurately esti-
mates GFR in patients with a solitary kidney, including
pediatric and adult populations with congenital renalKidney International Reports (2019) 4, 1205–1218
Table 5. Comparing methods of glomerular ﬁltration rate estimation in different populations with a solitary kidney
Reference n
Age of study
population (yr)
Causes of a
solitary kidney
Reference
method of GFR
measurement eGFR
Misclassiﬁcation
of CKD stage
Pierrat et al.
200381
176 Children 3–19 (mean:
13.2  0.36)
Adults 20–75 (mean:
46  1.23)
Children: 30 patients with SK
and 30 patients with KT
Adult: 28 patients with SK and
88 patients with KT
Corrected Cin
CrClm
CrClCG
Schwartz82
GFR (Sch)
MDRD GFR
Children: Means of Sch and MDRD GFR
overestimated mean of Cin
Adult: Mean of CrClCG and of MDRD GFR
were not different from Cin.
In SK, mean MDRD GFR underestimated Cin
CrCl overestimated Cin
Tan et al.
201083
64 21–70 (median: 49) Living kidney donation with
median time after donation of
13 months
iGFR Urinary CrCl
CrClm
4-variable MDRD estimating
equation (eGFR)
CKD-EPI GFR estimating
equation
CrCl overestimates iGFR
Both Cr-based estimating equations
underestimated and were poorly correlated
with iGFR
Misclassiﬁcation was greater in donors
aged $ 55 yr
Ferreira-Filho
et al.
201184
36 Mean: 50.7  10.6 Living kidney donation 28
patients
Renal stones with
hydronephrosis, 8 patients
Mean duration after unilateral
nephrectomy: 11.6  9 (2
mon to 38 yr)
CrClm  CrCl
 CrClCG
 MDRD GFR
CrClCG had a better correlation with CrClm
than MDRD GFR (r2 0.64 vs. 0.34,
respectively).
At CrClm of >90 ml/min per m
2, CrClCG
and MDRD GFR underestimate CrClm
At CrClm <90 ml/min per m
2, CrClCG and
MDRD GFR overestimate CrClm
Westland et al.
201385
77 1.5–19.8 Congenital, 26 patients
(34%)
Acquired, 51 patients (66%)
GFR-inulin 2 Cr-based (eGFR [eGFR]-
Schwartz,82 urinary CrCl); 2
cystatin C–based (eGFR-
Zappitelli1,86 eGFR-CKiD 1);
and 2 cystatin C/Cr–based
(eGFR-Zappitelli2,86
eGFR-CKiD2)
eGFR-CKiD2 (height, sex, serum creatinine,
cystatin C, and BUN)
Mean bias 20.9 ml/min per 1.73 m2
95% of values within 30% of GFR-inulin
54% of values within 10% of GFR-inulin
BUN, blood urea nitrogen; Cin, inulin clearance; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; CKiD, Chronic Kidney Disease in Children;
CrCl, creatinine clearance; CrClCG, creatinine clearance by Cockroft-Gault equation; CrClm, creatinine clearance from a 24-hour urine collection; eGFR, estimated glomerular filtration
rate; GFR, glomerular filtration rate; iGFR, urinary iothalamate clearance; MDRD, Modification of Diet in Renal Disease; Sch, estimated glomerular filtration rate by Schwartz (Schwartz ¼
K  height (cm)/Pcr (mg/dl) where K ¼ 0.55 for children aged 2 to 12 years, K ¼ 0.55 for girls 13 to 21 years, K ¼ 0.70 for boys 13 to 21 years, and Pcr ¼ serum creatinine [mg/dl])82; SK,
single kidney; KT, kidney transplantation.
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diseases, as well as adult living kidney donors
(Table 5).81–86
Cystatin C is an endogenous kidney ﬁltration marker
that may overcome some of the limitations of creati-
nine. Cystatin C is freely ﬁltrated and not reabsorbed;
however, it is metabolized by renal tubular cells. The
combined cystatin C and creatinine-based eGFR for-
mulas (eGFR-CKiD [chronic kidney disease in children
2]) that include height, sex, serum creatinine, cystatin
C, and blood urea nitrogen may provide a better esti-
mated GFR than creatinine-based or cystatin-based GFR
in children with a solitary functioning kidney.85
As discussed above, persons with a solitary kidney
often develop glomerular hyperﬁltration after ne-
phrectomy, which occurs as early as the ﬁrst week
postoperatively and can continue for longer than 10
years.87 Creatinine is not an ideal marker of GFR given
that it is not a perfect ﬁltration marker and is secreted
and reabsorbed by renal tubules. Hyperﬁltration is
deﬁned as a high ﬁltration fraction of >18% in pedi-
atric patients with various renal diseases, decreased
effective renal plasma ﬂow, and subsequently, lowered
creatinine in the peritubular capillary. Decreased
creatinine in the peritubular capillary lowers renal
tubular creatinine secretion88 and has a slight effect ofKidney International Reports (2019) 4, 1205–1218increasing renal tubular creatinine reabsorption.89
These lead to underestimated GFR. Tan et al.83 re-
ported that the Modiﬁcation of Diet in Renal Disease
and the Chronic Kidney Disease Epidemiology Collab-
oration GFR estimating equations underestimated GFR,
especially in living kidney donors $55 years old.
Different from creatinine-based eGFR, cystatin C–based
eGFR is not affected by a high ﬁltration fraction or
hyperﬁltration;88 however, cystatin-based or creatinine–
cystatin C–based GFR have less accuracy in identifying
living kidney donors with measured GFR <60 ml/min
per 1.73 m2; therefore, creatinine-based eGFR remains
the preferred method to follow up on renal function after
living kidney donation.90
Given the limitations of eGFR, measured GFR should
be used, particularly when a more accurate GFR
assessment is necessary for clinical decision making
(Table 4).78 For instance, a patient with renal cell car-
cinoma and solitary kidney may receive renally toxic
chemotherapy, in which case more accurate assessment
and monitoring of GFR is prudent. A measured GFR
can be performed by 24-hour urine collections or by
assessing ﬁltration markers that can be either endoge-
nous or exogenous. A 24-hour urine test for creatinine
clearance is a classic approach; however, it is incon-
venient and can overestimate the true GFR due to renal1215
REVIEW E Tantisattamo et al.: Postnephrectomy Managementtubular creatinine secretion. Two commonly used
ﬁltration markers are iothalamate and iohexol clear-
ances. In addition, there are other ﬁltration markers
whose advantages and limitations are summarized in
Table 4.
Albuminuria Measurement
In the setting of postnephrectomy for living kidney
donation or any other reason, proteinuria may emerge and
worsen over time. A meta-analysis including 48 studies
with a total of 5048 donors revealed that an average 24-
hour urine protein was 154 mg/d, and the average GFR
was 86 ml/min over an average 7 years postdonation.91
The 2017 Kidney Disease Improving Global Outcomes
guidelines recommend checking assessment and moni-
toring of albuminuria in living kidney donors at least once
a year for early detection of proteinuria.29
Conclusions
Persons with a normal functioning solitary kidney are
likely at higher risk of developing CKD and of pro-
gression to ESRD, whereas the absolute risk remains
small compared to that in the general population.
Consistent data suggest an association between higher
dietary protein intake and glomerular hyperﬁltration
and risk of CKD incidence and progression in those
with less nephron endowment, including those with a
solitary kidney. Additionally, data support the role of
nutrition and dietary management to mitigate any
future risk for CKD progression; however, there is no
strong evidence demonstrating beneﬁts from several
interventions in patients with a solitary kidney. Rec-
ommendations pertaining to lifestyle modiﬁcations and
nutrition for patients who have undergone or will
undergo nephrectomy are warranted to achieve the
goal of maintaining longevity and health similar to that
in the general population.
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